Loading...

Susana Ortiz-Urda, MD, PhD

Title(s)Assistant Professor, Dermatology
SchoolSchool of Medicine
Phone415-476-8502
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of ViennaM.D.1998School of Medicine
    Rappersberger, University of ViennaPhD1998Biology
    University of ViennaResearch Fellow1999Dermatology
    AKH ViennaResearch Resident2001Dermatology
    Stanford UniversityPostdoctoral Fellowship2005Epithelial Biology
    The Brooklyn Hospital Center, NYInternship2006Medicine
    Stanford UniversityResident2010Dermatology
    University of California, San Francisco Research Fellowship 2010Derm-Oncology
    New York University, NYM.B.A.2014Business Administration

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Posch C, Cholewa BD, Vujic I, Sanlorenzo M, Ma J, Kim ST, Kleffel S, Schatton T, Rappersberger K, Gutteridge R, Ahmad N, Ortiz/Urda S. Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma. J Invest Dermatol. 2015 Oct; 135(10):2475-2483. PMID: 26016894.
      View in: PubMed
    2. Curl P, Vujic I, van 't Veer LJ, Ortiz-Urda S, Kahn JG. Correction: Cost-Effectiveness Of Treatment Strategies for BRAF-Mutated Metastatic Melanoma. PLoS One. 2015; 10(4):e0126988. PMID: 25893993.
      View in: PubMed
    3. Sanlorenzo M, Vujic I, Posch C, Cleaver JE, Quaglino P, Ortiz-Urda S. The risk of melanoma in pilots and cabin crew: UV measurements in flying airplanes. JAMA Dermatol. 2015 Apr; 151(4):450-2. PMID: 25517516.
      View in: PubMed
    4. Algazi AP, Cha E, Ortiz-Urda SM, McCalmont T, Bastian BC, Hwang J, Pampaloni MH, Behr S, Chong K, Cortez B, Quiroz A, Coakley F, Liu S, Daud AI. The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. Br J Cancer. 2015 Apr 14; 112(8):1326-31. PMID: 25867272.
      View in: PubMed
    5. Posch C, Latorre A, Crosby MB, Celli A, Latorre A, Vujic I, Sanlorenzo M, Green GA, Weier J, Zekhtser M, Ma J, Monico G, Char DH, Jusufbegovic D, Rappersberger K, Somoza Á, Ortiz-Urda S. Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticles. Biomed Microdevices. 2015 Feb; 17(1):15. PMID: 25653058.
      View in: PubMed
    6. Vujic I, Sanlorenzo M, Posch C, Esteve-Puig R, Yen AJ, Kwong A, Tsumura A, Murphy R, Rappersberger K, Ortiz-Urda S. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget. 2015 Jan 20; 6(2):969-78. PMID: 25504439.
      View in: PubMed
    7. Sanlorenzo M, Wehner MR, Linos E, Kornak J, Kainz W, Posch C, Vujic I, Johnston K, Gho D, Monico G, McGrath JT, Osella-Abate S, Quaglino P, Cleaver JE, Ortiz-Urda S. The risk of melanoma in airline pilots and cabin crew: a meta-analysis. JAMA Dermatol. 2015 Jan; 151(1):51-8. PMID: 25188246.
      View in: PubMed
    8. Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014 Dec; 71(6):1102-1109.e1. PMID: 25440439.
      View in: PubMed
    9. Vujic I, Posch C, Sanlorenzo M, Yen AJ, Tsumura A, Kwong A, Feichtenschlager V, Lai K, Arneson DV, Rappersberger K, Ortiz-Urda SM. Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies. Oncotarget. 2014 Sep 15; 5(17):7936-44. PMID: 25277205.
      View in: PubMed
    10. Curl P, Vujic I, van 't Veer LJ, Ortiz-Urda S, Kahn JG. Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma. PLoS One. 2014; 9(9):e107255. PMID: 25198196.
      View in: PubMed
    11. Vujic I, Marker M, Posch C, Mühlehner D, Monshi B, Breier F, Steiner A, Ortiz-Urda S, Rappersberger K. Merkel cell carcinoma: mitoses, expression of Ki-67 and bcl-2 correlate with disease progression. J Eur Acad Dermatol Venereol. 2015 Mar; 29(3):542-8. PMID: 25088273.
      View in: PubMed
    12. Latorre A, Posch C, Garcimartín Y, Celli A, Sanlorenzo M, Vujic I, Ma J, Zekhtser M, Rappersberger K, Ortiz-Urda S, Somoza Á. DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics. Nanoscale. 2014 Jul 07; 6(13):7436-42. PMID: 24882040.
      View in: PubMed
    13. Latorre A, Posch C, Garcimartín Y, Ortiz-Urda S, Somoza Á. Single-point mutation detection in RNA extracts using gold nanoparticles modified with hydrophobic molecular beacon-like structures. Chem Commun (Camb). 2014 Mar 21; 50(23):3018-20. PMID: 24496380.
      View in: PubMed
    14. Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum MD, Algazi A, Osella-Abate S, Quaglino P, Daud A, Ortiz-Urda S. Melanoma immunotherapy. Cancer Biol Ther. 2014 Jun 01; 15(6):665-74. PMID: 24651672.
      View in: PubMed
    15. Vujic I, Shroff A, Grzelka M, Posch C, Monshi B, Sanlorenzo M, Ortiz-Urda S, Rappersberger K. Mycoplasma pneumoniae-associated mucositis--case report and systematic review of literature. J Eur Acad Dermatol Venereol. 2015 Mar; 29(3):595-8. PMID: 24665876.
      View in: PubMed
    16. Posch C, Weihsengruber F, Bartsch K, Feichtenschlager V, Sanlorenzo M, Vujic I, Monshi B, Ortiz-Urda S, Rappersberger K. Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients. Br J Cancer. 2014 Mar 18; 110(6):1427-32. PMID: 24518593.
      View in: PubMed
    17. Posch C, Ortiz-Urda S. NRAS mutant melanoma--undrugable? Oncotarget. 2013 Apr; 4(4):494-5. PMID: 23660168.
      View in: PubMed
    18. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A. 2013 Mar 05; 110(10):4015-20. PMID: 23431193.
      View in: PubMed
    19. Chong K, Daud A, Ortiz-Urda S, Arron ST. Cutting edge in medical management of cutaneous oncology. Semin Cutan Med Surg. 2012 Jun; 31(2):140-9. PMID: 22640435.
      View in: PubMed
    20. Reuter JA, Ortiz-Urda S, Kretz M, Garcia J, Scholl FA, Pasmooij AM, Cassarino D, Chang HY, Khavari PA. Modeling inducible human tissue neoplasia identifies an extracellular matrix interaction network involved in cancer progression. Cancer Cell. 2009 Jun 02; 15(6):477-88. PMID: 19477427.
      View in: PubMed
    21. Waterman EA, Sakai N, Nguyen NT, Horst BA, Veitch DP, Dey CN, Ortiz-Urda S, Khavari PA, Marinkovich MP. A laminin-collagen complex drives human epidermal carcinogenesis through phosphoinositol-3-kinase activation. Cancer Res. 2007 May 01; 67(9):4264-70. PMID: 17483338.
      View in: PubMed
    22. Ortiz-Urda S, Garcia J, Green CL, Chen L, Lin Q, Veitch DP, Sakai LY, Lee H, Marinkovich MP, Khavari PA. Type VII collagen is required for Ras-driven human epidermal tumorigenesis. Science. 2005 Mar 18; 307(5716):1773-6. PMID: 15774758.
      View in: PubMed
    23. Marker M, Ortiz-Urda S, Lilgenau N, Rappersberger K. [Erythema induratum-nodular vasculitis]. J Dtsch Dermatol Ges. 2004 Mar; 2(3):206-14; quiz 215. PMID: 16281639.
      View in: PubMed
    24. Valencak J, Ortiz-Urda S, Heere-Ress E, Kunstfeld R, Base W. Carbamazepine-induced DRESS syndrome with recurrent fever and exanthema. Int J Dermatol. 2004 Jan; 43(1):51-4. PMID: 14693022.
      View in: PubMed
    25. Ortiz-Urda S, Elbe-Bürger A, Smolle J, Marquart Y, Chudnovsky Y, Ridky TW, Bernstein P, Wolff K, Rappersberger K. The plant lectin wheat germ agglutinin inhibits the binding of pemphigus foliaceus autoantibodies to desmoglein 1 in a majority of patients and prevents pathomechanisms of pemphigus foliaceus in vitro and in vivo. J Immunol. 2003 Dec 01; 171(11):6244-50. PMID: 14634141.
      View in: PubMed
    26. Ortiz-Urda S, Lin Q, Yant SR, Keene D, Kay MA, Khavari PA. Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer. Gene Ther. 2003 Jul; 10(13):1099-104. PMID: 12808440.
      View in: PubMed
    27. Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Calos MP, Khavari PA. PhiC31 integrase-mediated nonviral genetic correction of junctional epidermolysis bullosa. Hum Gene Ther. 2003 Jun 10; 14(9):923-8. PMID: 12828862.
      View in: PubMed
    28. Ortiz-Urda S, Rappersberger K. [New immunosuppressive agents for treating psoriasis]. Hautarzt. 2003 Mar; 54(3):230-6. PMID: 12634991.
      View in: PubMed
    29. Ortiz-Urda S, Lin Q, Green CL, Keene DR, Marinkovich MP, Khavari PA. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J Clin Invest. 2003 Jan; 111(2):251-5. PMID: 12531881.
      View in: PubMed
    30. Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Fang M, Calos MP, Khavari PA. Stable nonviral genetic correction of inherited human skin disease. Nat Med. 2002 Oct; 8(10):1166-70. PMID: 12244305.
      View in: PubMed
    31. Schmuth M, Yosipovitch G, Williams ML, Weber F, Hintner H, Ortiz-Urda S, Rappersberger K, Crumrine D, Feingold KR, Elias PM. Pathogenesis of the permeability barrier abnormality in epidermolytic hyperkeratosis. J Invest Dermatol. 2001 Oct; 117(4):837-47. PMID: 11676820.
      View in: PubMed
    32. Schaeppi H, Bauer JW, Hametner R, Metze D, Ortiz-Urda S, Salmhofer W, Rappersberger K, Hintner H. A localized variant of paraneoplastic pemphigus: acantholysis associated with malignant melanoma. Br J Dermatol. 2001 Jun; 144(6):1249-54. PMID: 11422052.
      View in: PubMed